Effect of the treatment modality for hepatocellular carcinoma on portal venous pressure

Bowen CHEN; Jiamin CHENG; Linzhi ZHANG; Jin LEI; Xiaoqiang GAO; Yinying LU

doi:10.3969/j.issn.1001-5256.2022.07.038

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1658-1661

PDF( 1848 KB)

Effect of the treatment modality for hepatocellular carcinoma on portal venous pressure

DOI: 10.3969/j.issn.1001-5256.2022.07.038

Bowen CHEN^{1, 2},
Jiamin CHENG²,
Linzhi ZHANG^{2, 3},
Jin LEI^{2, 4},
Xiaoqiang GAO^{2, 4},
Yinying LU^{1, 2, 5
,
,
,}

1.
Peking University 302 Clinical Medical School, Beijing 100039, China
2.
Senior Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
3.
Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
4.
Guizhou Medical University Clinical Medical School, Guiyang 550004, China
5.
Guangdong Key Laboratory of Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518055, China

Research funding:

Special Program of Sustainable Development Issued by the Science, Technology and Innovation Commission of Shenzhen Municipality (KCXFZ202002011006448)

More Information

Corresponding author: LU Yinying, luyinying1973@163.com(ORCID: 0000-0002-7737-2334)
Received Date: 2021-12-13
Accepted Date: 2022-01-27
Published Date: 2022-07-20

Abstract

Abstract

Portal hypertension (PH) on the basis of liver cirrhosis is a common complication of hepatocellular carcinoma (HCC), and it is also a key factor affecting treatment decisions and prognosis. Different treatment modalities for HCC may have different effects on portal venous pressure. Through a literature review, it is concluded that hepatectomy, repeated transcatheter arterial chemoembolization, oxaliplatin chemotherapy, and lenvatinib can lead to the increase in portal venous pressure, while sorafenib and regorafenib have been proved to reduce portal venous pressure within a short term in clinical trials and/or animal experiments. There are also reports on the effect of novel combination treatment regimens (such as atezolizumab combined with bevacizumab) and newly marketed first-line or second-line targeted drugs for HCC (such as donafenib, apatinib, and anlotinib) on portal hypertension-related complications including gastrointestinal bleeding in related clinical trials, but further studies are needed to investigate their overall effect on portal venous pressure.
- Carcinoma, Hepatocellular,
- Antineoplastic Protocols,
- Portal Pressure

FullText(HTML)

References(37)

References

[1]	ZHAO LH, JIA JD. Etiological diagnosis and standard treatment of portal hypertension should be taken seriously[J]. J Clin Hepatol, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001. 赵连晖, 贾继东. 应重视门静脉高压症的病因诊断及规范治疗[J]. 临床肝胆病杂志, 2019, 35(1): 10-12. DOI: 10.3969/j.issn.1001-5256.2019.01.001.
[2]	WANG WD. Diagnosis and treatment of hepatocellular carcinoma with portal hypertension[J]. World Chin J Dig, 2018, 26(24): 1429-1433. DOI: 10.11569/wcjd.v26.i24.1429. 王卫东. 肝癌合并门静脉高压症的诊治现状[J]. 世界华人消化杂志, 2018, 26(24): 1429-1433. DOI: 10.11569/wcjd.v26.i24.1429.
[3]	RIPOLL C, GROSZMANN RJ, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis[J]. J Hepatol, 2009, 50(5): 923-928. DOI: 10.1016/j.jhep.2009.01.014.
[4]	ZHONG JH, KE Y, GONG WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2): 329-340. DOI: 10.1097/SLA.0000000000000236.
[5]	REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. DOI: 10.1016/j.jhep.2021.11.018.
[6]	XU XF, XING H, HAN J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J]. JAMA Surg, 2019, 154(3): 209-217. DOI: 10.1001/jamasurg.2018.4334.
[7]	GUO ZY, HONG Y. Advances in the throughout assessment and management of surgical resection for liver cancer and cirrhotic completed with portal hypertension[J]. J Clin Surg, 2021, 29(11): 1092-1095. DOI: 10.3969/j.issn.1005-6483.2021.11.028. 郭张有, 洪源. 肝硬化门静脉高压症肝癌手术切除全程评估和管理的进展[J]. 临床外科杂志, 2021, 29(11): 1092-1095. DOI: 10.3969/j.issn.1005-6483.2021.11.028.
[8]	BOGNER A, REISSFELDER C, STRIEBEL F, et al. Intraoperative increase of portal venous pressure is an immediate predictor of posthepatectomy liver failure after major hepatectomy: a prospective study[J]. Ann Surg, 2021, 274(1): e10, e17. DOI: 10.1097/SLA.0000000000003496.
[9]	LAN X, ZHANG H, LI H, et al. Dynamic changes of portal vein pressure gradient under different degrees of liver cirrhosis and resection volume in the first week post hepatectomy[J]. Hepatol Res, 2018, 48(12): 978-988. DOI: 10.1111/hepr.13197.
[10]	NI YB, ZHU JY. Resection of hepatocellular carcinoma with portal hypertension[J]. J Hepatobiliary Sur, 2017, 25(5): 321-322. DOI: 10.3969/j.issn.1006-4761.2017.05.001. 倪彦彬, 朱继业. 合并门静脉高压的肝癌切除术[J]. 肝胆外科杂志, 2017, 25(5): 321-322. DOI: 10.3969/j.issn.1006-4761.2017.05.001.
[11]	CARRAPITA JG, ROCHA C, DONATO H, et al. Portal venous pressure variation during hepatectomy: a prospective study[J]. Acta Med Port, 2019, 32(6): 420-426. DOI: 10.20344/amp.10892.
[12]	SHEN ZF, LIANG X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension[J]. World J Clin Cases, 2021, 9(11): 2419-2432. DOI: 10.12998/wjcc.v9.i11.2419.
[13]	LI XL, ZHU XD, XIAO N, et al. A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study[J]. Surgery, 2020, 167(6): 926-932. DOI: 10.1016/j.surg.2020.01.013.
[14]	ABBAS MS, MOHAMED KS, IBRAHEIM OA, et al. Effects of terlipressin infusion on blood loss and transfusion needs during liver resection: A randomised trial[J]. Acta Anaesthesiol Scand, 2019, 63(1): 34-39. DOI: 10.1111/aas.13226.
[15]	VILLANUEVA A. Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
[16]	YANG W, YAN K, GOLDBERG SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment[J]. World J Gastroenterol, 2016, 22(10): 2993-3005. DOI: 10.3748/wjg.v22.i10.2993.
[17]	LEE S, JEONG WK, RHIM H. Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: assessment of safety based on liver function and portal hypertension parameters[J]. J Vasc Interv Radiol, 2014, 25(10): 1573-1579. DOI: 10.1016/j.jvir.2014.06.015.
[18]	KHISTI R, PATIDAR Y, GARG L, et al. Correlation of baseline portal pressure (hepatic venous pressure gradient) and indocyanine green clearance test with post-transarterial chemoembolization acute hepatic failure[J]. J Clin Exp Hepatol, 2019, 9(4): 447-452. DOI: 10.1016/j.jceh.2018.09.004.
[19]	SCHEINER B, ULBRICH G, MANDORFER M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma[J]. United European Gastroenterol J, 2019, 7(6): 850-858. DOI: 10.1177/2050640619840199.
[20]	LIU K, MIN XL, PENG J, et al. The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma[J]. J Clin Med Res, 2016, 8(4): 297-302. DOI: 10.14740/jocmr2496w.
[21]	PUENTE A, FORTEA JI, DEL POZO C, et al. Porto-sinusoidal vascular disease associated to oxaliplatin: an entity to think about It[J]. Cells, 2019, 8(12): 1506. DOI: 10.3390/cells8121506.
[22]	KATAMURA Y, AIKATA H, TAKAKI S, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis[J]. J Gastroenterol, 2009, 44(5): 492-502. DOI: 10.1007/s00535-009-0033-y.
[23]	DA FONSECA LG, REIG M, BRUIX J. Tyrosine kinase inhibitors and hepatocellular carcinoma[J]. Clin Liver Dis, 2020, 24(4): 719-737. DOI: 10.1016/j.cld.2020.07.012.
[24]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
[25]	WEI L, WAN H. Roles of hemodynamic alterations in portal hypertension and cirrhosis[J]. J Clin Hepatol, 2013, 29(4): 308-310. DOI: 10.3969/j.issn.1001-5256.2013.04.019. 魏丽, 万红. 门静脉高压症血流动力学改变的发病机理[J]. 临床肝胆病杂志, 2013, 29(4): 308-310. DOI: 10.3969/j.issn.1001-5256.2013.04.019.
[26]	ZHU Y, CHENG Y, LI AM, et al. Therapeutic effect of sorafeinib on portal hypertension: research progress and mechanisms[J]. J Southern Med Univ, 2014, 34(1): 133-136. DOI: 10.12122/j.issn.1673-4254.2014.01.030. 朱云, 程旸, 李爱民, 等. 索拉非尼对门静脉高压症的治疗作用及其机制[J]. 南方医科大学学报, 2014, 34(1): 133-136. DOI: 10.12122/j.issn.1673-4254.2014.01.030.
[27]	HIDAKA H, UOJIMA H, NAKAZAWA T, et al. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study[J]. Hepatol Res, 2020, 50(9): 1083-1090. DOI: 10.1111/hepr.13531.
[28]	OHYA K, KAWAOKA T, NAMBA M, et al. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy[J]. Sci Rep, 2019, 9(1): 12101. DOI: 10.1038/s41598-019-48045-z.
[29]	KUDO M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer, 2018, 7(1): 1-19. DOI: 10.1159/000487148.
[30]	USCHNER FE, SCHUELLER F, NIKOLOVA I, et al. The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension[J]. Oncotarget, 2018, 9(90): 36220-36237. DOI: 10.18632/oncotarget.26333.
[31]	FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[32]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[33]	XU J, SHEN J, GU S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A Nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571.
[34]	LU W, JIN XL, YANG C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438. DOI: 10.1080/15384047.2017.1323589.
[35]	MEI K, QIN S, CHEN Z, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/Ⅱ trial[J]. J Immunother Cancer, 2021, 9(3): e002191. DOI: 10.1136/jitc-2020-002191.
[36]	SUN Y, ZHOU A, ZHANG W, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase Ⅱ study (ALTER-0802 study)[J]. Hepatol Int, 2021, 15(3): 621-629. DOI: 10.1007/s12072-021-10171-0.
[37]	SHIN SW, AHN KS, KIM SW, et al. Liver resection versus local ablation therapies for hepatocellular carcinoma within the milan criteria: a systematic review and meta-analysis[J]. Ann Surg, 2021, 273(4): 656-666. DOI: 10.1097/SLA.0000000000004350.

Relative Articles

[1]	Zexin HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 175-180. doi: 10.12449/JCH240129
[2]	Wencong DAI, Mengya ZANG, Guosheng YUAN, Qi LI, Rong LI, Wenli LI, Shuyu DONG, Jinzhang CHEN. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2023, 39(7): 1592-1599. doi: 10.3969/j.issn.1001-5256.2023.07.013
[3]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[4]	Sirou LI, Yuanlong ZHOU, Keliang LIU, Zhibo LIANG, Jinghua LI. Conversion therapy for massive hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(7): 1612-1615. doi: 10.3969/j.issn.1001-5256.2022.07.028
[5]	Kailing XIE, Feng XU. Mechanism of action of Huaier granules in treatment of hepatocellular carcinoma and advances in its clinical application[J]. Journal of Clinical Hepatology, 2022, 38(3): 676-681. doi: 10.3969/j.issn.1001-5256.2022.03.038
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Zhiyuan HOU, Yuan LIU, Chaoran YANG, Jisen ZHAO, Shujie CHENG. Current research status and prospect of circulating tumor DNA in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2616-2620. doi: 10.3969/j.issn.1001-5256.2022.11.036
[8]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[9]	Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037
[10]	Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040
[11]	Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
[12]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[13]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[14]	Wang XiaoYun, Li LinFeng, Guo Quan, Ceng YiLan, Li HaiYang, Du YingRong, Chen Gang, Liang YueDong, Lu YinYing. Development and enlightenment of intelligentized diagnostic and therapeutic mode for hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2360-2364. doi: 10.3969/j.issn.1001-5256.2019.10.051
[15]	Shang ZhiYin, Yang JingMao, Chen LiPing, Liu Min, Cheng Kai, Li YaoHua, Ai YingChun, Cheng JiLin. Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations[J]. Journal of Clinical Hepatology, 2017, 33(2): 354-358. doi: 10.3969/j.issn.1001-5256.2017.02.034
[16]	Xu ZhengGuo, Zhao YongBing, Zheng YuanYu, Liu En, Yang ShiMing. Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2016.12.019
[17]	Shi XiaoJu, Lyu GuoYue, Zhang Ping, Du XiaoHong, Wang GuangYi. Postoperative application of multidisciplinary treatment in patients with hepatobiliary and pancreatic malignancies[J]. Journal of Clinical Hepatology, 2015, 31(11): 1886-1888. doi: 10.3969/j.issn.1001-5256.2015.11.028
[18]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Strategy and method of multi-disciplinary comprehensive treatment of liver cancer-consensus of experts in Guangdong, China (2)[J]. Journal of Clinical Hepatology, 2014, 30(11): 1116-1119. doi: 10.3969/j.issn.1001-5256.2014.11.005
[19]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[20]	Wang JiYao. Importance of detecting portal hypertension in liver cirrhosis patients: theory, research tools, and clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 642-643.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (625) PDF downloads(66)

Effect of the treatment modality for hepatocellular carcinoma on portal venous pressure

DOI: 10.3969/j.issn.1001-5256.2022.07.038

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of the treatment modality for hepatocellular carcinoma on portal venous pressure

DOI: 10.3969/j.issn.1001-5256.2022.07.038

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content